BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 32777103)

  • 1. Survival analysis in treated plasmablastic lymphoma patients: a population-based study.
    Florindez JA; Alderuccio JP; Reis IM; Lossos IS
    Am J Hematol; 2020 Nov; 95(11):1344-1351. PubMed ID: 32777103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insurance status impacts overall survival in Burkitt lymphoma.
    Goldstein JS; Switchenko JM; Behera M; Flowers CR; Koff JL
    Leuk Lymphoma; 2019 Dec; 60(13):3225-3234. PubMed ID: 31274033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiologic Characteristics, Treatment Patterns, and Survival Analysis of Plasmablastic Lymphoma in the United States: A SEER and NCDB Analysis.
    Hansen AR; Vardell VA; Fitzgerald LA
    Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e152-e160.e3. PubMed ID: 38262787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasmablastic lymphoma - single centre experience with infusional EPOCH chemotherapy.
    Jayachandran PK; Rajan AK; Karunakaran P; Mehra N; Selvarajan G; Kesana S; Dhanushkodi M; Radhakrishnan V; Sagar TG
    Leuk Res; 2020 Aug; 95():106391. PubMed ID: 32559556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human immunodeficiency virus-negative plasmablastic lymphoma: a comprehensive analysis of 114 cases.
    Liu M; Liu B; Liu B; Wang Q; Ding L; Xia C; Dong L
    Oncol Rep; 2015 Apr; 33(4):1615-20. PubMed ID: 25695332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological analysis of oral plasmablastic lymphoma: A systematic review.
    Rodrigues-Fernandes CI; de Souza LL; Santos-Costa SFD; Silva AMB; Pontes HAR; Lopes MA; de Almeida OP; Brennan PA; Fonseca FP
    J Oral Pathol Med; 2018 Nov; 47(10):915-922. PubMed ID: 29917262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical characteristics and survival analysis of 15 cases of HIV-negative plasmablastic lymphoma].
    Fu WJ; He MX; Huang AJ; Gao L; Lu GH; Chen J; Chen L; Ni X; Zhang WP; Wang JM; Yang JM
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):456-461. PubMed ID: 32654457
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical characteristics and survival analysis of eight cases HIV-negative plasmablastic lymphoma].
    Han X; Hu LX; Ouyang MQ; Duan MH; Zhou DB
    Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):290-294. PubMed ID: 28468089
    [No Abstract]   [Full Text] [Related]  

  • 9. Plasmablastic lymphoma: Review of 60 Chinese cases and prognosis analysis.
    Han X; Duan M; Hu L; Zhou D; Zhang W
    Medicine (Baltimore); 2017 Mar; 96(9):e5981. PubMed ID: 28248855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatments and Outcomes in Stage I Extranodal Marginal Zone Lymphoma in the United States.
    Alderuccio JP; Florindez JA; Reis IM; Zhao W; Lossos IS
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33918801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients.
    Loghavi S; Alayed K; Aladily TN; Zuo Z; Ng SB; Tang G; Hu S; Yin CC; Miranda RN; Medeiros LJ; Khoury JD
    J Hematol Oncol; 2015 Jun; 8():65. PubMed ID: 26055271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases.
    Morscio J; Dierickx D; Nijs J; Verhoef G; Bittoun E; Vanoeteren X; Wlodarska I; Sagaert X; Tousseyn T
    Am J Surg Pathol; 2014 Jul; 38(7):875-86. PubMed ID: 24832164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The incidence and survival outcomes of patients with primary cardiac lymphoma: A SEER-based analysis.
    Xiao M; Lin J; Xiao T; Lin Y; Ye Y
    Hematol Oncol; 2020 Aug; 38(3):334-343. PubMed ID: 32311106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic features of plasmablastic lymphoma: Single-center series of 8 cases from Saudi Arabia.
    Elyamany G; Alzahrani AM; Aljuboury M; Mogadem N; Rehan N; Alsuhaibani O; Alabdulaaly A; Al-Mussaed E; Elhag I; AlFiaar A
    Diagn Pathol; 2015 Jun; 10():78. PubMed ID: 26108914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and pathological aspects of human immunodeficiency virus-associated plasmablastic lymphoma: analysis of 24 cases.
    Koizumi Y; Uehira T; Ota Y; Ogawa Y; Yajima K; Tanuma J; Yotsumoto M; Hagiwara S; Ikegaya S; Watanabe D; Minamiguchi H; Hodohara K; Murotani K; Mikamo H; Wada H; Ajisawa A; Shirasaka T; Nagai H; Kodama Y; Hishima T; Mochizuki M; Katano H; Okada S
    Int J Hematol; 2016 Dec; 104(6):669-681. PubMed ID: 27604616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic features, management, and outcomes of plasmablastic lymphoma: A 10-year experience.
    Arora N; Eule C; Gupta A; Li HC; Sadeghi N
    Am J Hematol; 2019 May; 94(5):E127-E129. PubMed ID: 30734351
    [No Abstract]   [Full Text] [Related]  

  • 17. Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study.
    Hess BT; Giri A; Park Y; Patel KK; Link BK; Nowakowski GS; Maliske SM; Fortin S; Chavez JC; Saeed H; Hill BT; Mejia Garcia AV; Maddocks KJ; Hanel W; Wagner-Johnston ND; Messmer MR; Kahl BS; Watkins M; Alderuccio JP; Lossos IS; Nathan S; Orellana-Noia VM; Portell CA; Landsburg DJ; Ayers EC; Castillo JJ
    Am J Hematol; 2023 Feb; 98(2):300-308. PubMed ID: 36588409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma Cell Myeloma - 20-Year Comparative Survival and Mortality of Three Plasma Cell Myeloma ICD-O-3 Oncologic Phenotypes by Age, Sex, Race, Stage, Cohort Entry Time-Period and Disease Duration: A Systematic Review of 111,041 Cases for Diagnosis Years 1973-2014: (SEER*Stat 8.3.4).
    Milano AF
    J Insur Med; 2018; 47(4):203-211. PubMed ID: 30668210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-treatment positron emission tomography-computed tomography is highly predictive of outcome in Plasmablastic lymphoma.
    Al Tabaa Y; Tchernonog E; Faurie P; Cottereau AS; Monjanel H; Bonnet A; Le Gouill S; Gyan E; Ghesquieres H; Mariano-Goulart D; Cartron G
    Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1705-1709. PubMed ID: 29679112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database.
    Castillo JJ; Winer ES; Olszewski AJ
    Am J Hematol; 2014 Mar; 89(3):310-4. PubMed ID: 24273125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.